Three Seoul-Listed Firms Unveil July 7 Share Sales and Bonus Issue

Three companies traded on South Korea’s two main boards disclosed capital actions in Seoul on July 7, with two turning to third-party share placements to bring in fresh cash and a third rewarding existing holders with additional stock. The most closely watched of the trio has a pharmaceutical maker stepping in as the named investor.

Ascendio Turns to a Pharmaceutical Buyer

Ascendio, a company listed on the main KOSPI board, said it would raise roughly 13.1 billion won through a paid-in capital increase placed with a single outside party. That party is Kyung Nam Pharm, which is taking the newly issued shares to fund facilities and related needs at Ascendio. On the other side of the transaction, Kyung Nam Pharm filed its own decision to acquire another company’s securities, confirming the purchase from the buyer’s ledger.

The identity of the investor gives the deal weight. Kyung Nam Pharm is a vitamin and health-supplement manufacturer headquartered in Uiryeong County, South Gyeongsang Province, best known for Lemona, the vitamin C product it first brought to market in the autumn of 1983. The company has been active on the deal front recently, having taken control of diagnostics maker Humasis in May 2024. Its move into Ascendio’s share register extends that pattern of outward investment.

Winhitech Places Shares With S&Global

On the KOSDAQ venture board, Winhitech disclosed a smaller placement of about 2 billion won, again through a third-party allotment rather than a rights offering to existing shareholders. The buyer is S&Global, and Winhitech pointed to operating funds among the intended uses. Third-party allotments of this kind let a company raise money quickly from a chosen investor without diluting through an open subscription, though they concentrate new ownership in a single hand.

Boosta Rewards Holders With a One-for-One Bonus Issue

Boosta, also on the KOSDAQ board, took a different route. Rather than seeking new money, it approved a bonus issue that hands shareholders one additional common share for every share already held. A bonus issue draws on internal reserves rather than outside capital, so it raises the share count without bringing in cash; the effect is to broaden the float and lower the per-share price while leaving each holder’s proportional stake unchanged.

The Common Thread

Taken together, the three disclosures show the range of tools Korean listed companies reach for on a single trading day: two used targeted placements to pull in outside capital for facilities and operations, while the third redistributed value it already held. For Ascendio in particular, the arrival of an established consumer-health manufacturer as its funding partner is the detail worth tracking, given Kyung Nam Pharm’s recent appetite for acquisitions.